Chimeric Endocrine Receptor T-Cell Therapy

CHICAGO — CD19 chimeric antigen receptor T-cell therapy improved lung function and skin thickness in patients with severe refractory systemic sclerosis, with 96% remaining off SSc treatment during follow-up, according to a speaker.

In this video, Stephen M. Ansell, MD, PhD, discusses research on the durability of bispecific antibodies, presented at ASH Annual Meeting and Exposition.

In this video, Brian T. Hill, MD, PhD, discusses research that evaluated the effectiveness of chemo-immunotherapy against three novel combination therapies in the second line or later for patients with relapsed/refractory large B-cell lymphoma.

In this video, Joshua Brody, MD, discusses an update of the ZUMA-7 trial, which was presented at ASCO Annual Meeting.

Axicabtagene ciloleucel significantly extended survival compared with historic standard of care in a curative setting for adults with previously untreated relapsed or refractory large B-cell lymphoma, according to the agent’s manufacturer.

The COVID-19 pandemic has exacerbated an already ongoing staffing crisis in oncology, as well as throughout the entire health care workforce, experts said.

NEW ORLEANS — In this video perspective, Rahul Banerjee, MD, FACP, discusses potentially practice-changing early research on treatments for newly diagnosed multiple myeloma presented at the ASH Annual Meeting and Exposition.

CMS recently announced new proposals to streamline the prior authorization process.